(Q34416830)

2 August 2017

Post marketing surveillance of captopril (for hypertension): a preliminary report (English)

1 reference

2 August 2017

Chalmers D

1

1 reference

2 August 2017

Dombey SL

series ordinal

2

1 reference

2 August 2017

Lawson DH

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 1987

1 reference

British Journal of Clinical Pharmacology

2 August 2017

1 reference

2 August 2017

24

1 reference

2 August 2017

3

1 reference

2 August 2017

343-349

1 reference

Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Postmarketing surveillance: practical experience with ketotifen

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Postmarketing surveillance of the safety of cimetidine: 12 month mortality report

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Drug rash with ampicillin and other penicillins

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Angiotensin-converting enzyme inhibitors: past, present, and bright future

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

Post-marketing surveillance of adverse reactions to new medicines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

A specific orally active inhibitor of angiotensin-converting enzyme in man.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1386256

The effects of antihypertensive therapy on the quality of life

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1987.TB03179.X

Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1987.TB03179.X

Monitoring adverse reactions to drugs.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3311104

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Methodology of monitored release of a new preparation: buprenorphine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3311104

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3311104

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.1987.TB03179.X

1 reference

2 August 2017

1 reference

2 August 2017

1 reference